Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449936 | 0.89 | ALDH1A1 (0.36) | TOP2ATOP2BENPP2KDRNPC1 | |
| SCHEMBL439443 | 0.81 | CYP2C19 (0.51) | ALDH1A1TBXA2RKMT2AGSTO1 | |
| SCHEMBL1578768 | 0.78 | HPGD (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL451746 | 0.78 | LMNA (0.41) | KDRALDH1A1EGFRMEN1KMT2A | |
| SCHEMBL453503 | 0.74 | GSTO1 (0.63) | GSTO1 | |
| SCHEMBL451865 | 0.71 | PRMT1 (0.46) | ALDH1A1 | |
| SCHEMBL603914 | 0.70 | CA1 (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL439442 | 0.69 | GSTO1 (0.44) | ALDH1A1GSTO1ACLY | |
| SCHEMBL30794423 | 0.69 | GSTO1 (0.44) | ALDH1A1GSTO1ACLY | |
| SCHEMBL448977 | 0.69 | CYP2C19 (0.46) | ALDH1A1MEN1KMT2AGSTO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466201-B2 | Potassium ion channel modulators and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-06-18 | — | — | US | claimed |
| EP-2231594-B1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | UNIV RAMOT (IL) | 2013-03-27 | — | — | EP | claimed |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | claimed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | claimed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20190216934-A9 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190105399-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | ENDOCYTE INC (US) | 2019-04-11 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-8105568-B2 | Vitamin receptor binding drug delivery conjugates | ENDOCYTE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | TOP2A 4202/4885TOP2B 3941/4885ENPP2 2090/4885 |
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | VDR, CYP2R1, CYP24A1 | TOP2A 3482/4885TOP2B 2901/4885ENPP2 1754/4885 |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | TOP2A 4202/4885TOP2B 3941/4885ENPP2 2090/4885 |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | KCNN3, SCN2B, SCN1B | TOP2A 3236/4885TOP2B 2606/4885ENPP2 1094/4885 |
| US-20190216934-A9 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | TOP2A 4145/4885TOP2B 3746/4885ENPP2 1923/4885 |
| US-20190105399-A1 | Vitamin-Receptor Binding Drug Delivery Conjugates | VDR, CYP2R1, CYP24A1 | TOP2A 4145/4885TOP2B 3746/4885ENPP2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.